An update on bacterial brain abscess in immunocompetent patients

R Sonneville1, R Ruimy2, N Benzonana3

  • 1Intensive Care Medicine and Infectious Diseases, AP-HP, Bichat Hospital, and UMR1148, LVTS, Sorbonne Paris Cité, INSERM/Paris Diderot University, Paris, France.

Abstract

Insights

Recent advances in brain abscess diagnosis and treatment have significantly improved outcomes for immunocompetent patients. Improved imaging, minimally invasive surgery, and new antibacterial agents offer better prognoses.

Area of Science:

  • Neuroscience
  • Infectious Diseases
  • Microbiology

Background:

  • A brain abscess is a focal infection of the brain, often originating from bacterial spread.
  • In immunocompetent individuals, bacteria cause over 95% of brain abscesses via contiguous spread or hematogenous dissemination.
  • Classic symptoms like headache, fever, and focal neurological deficits are present in only about 20% of patients.

Purpose of the Study:

  • To review recent advancements in the diagnosis and management of brain abscesses.

Main Methods:

  • A literature search was conducted using Medline and Embase databases.
  • Articles published between 2012 and 2016 were included.
  • Keywords used were 'brain' and 'abscess'.

Main Results:

  • Magnetic resonance imaging (MRI) with contrast is the gold standard for diagnosing brain abscesses.
  • Stereotactic aspiration of lesions before antimicrobial therapy is recommended for optimal microbiological documentation.
  • Empirical treatment should cover common pathogens including streptococci, staphylococci, anaerobes, and Enterobacteriaceae.
  • A 6-week course of a third-generation cephalosporin and metronidazole is effective for community-acquired brain abscesses in immunocompetent patients.

Conclusions:

  • Advances in brain imaging, minimally invasive surgery, molecular biology, and antimicrobial agents have significantly improved brain abscess prognosis.
  • Optimal management involves timely diagnosis, appropriate surgical intervention, and targeted antimicrobial therapy.
  • Continued research in molecular diagnostics and novel antibacterial agents holds promise for further enhancing patient outcomes.